title: Stress-induced wall motion abnormalities with low-dose dobutamine infusion indicate the presence of severe disease and vulnerable myocardium.
abstract: BACKGROUND
  Patients with left ventricular (LV) systolic dysfunction due to coronary artery disease (CAD) may develop stress-induced wall motion abnormalities (SWMA) with low-dose (10 microg/kg/min) dobutamine infusion. The clinical significance of low-dose SWMA is unknown.
  
  
  OBJECTIVE
  We investigated the clinical, hemodynamic and angiographic correlates of low-dose SWMA in patients with chronic ischemic LV systolic dysfunction.
  
  
  METHODS
  Seventy patients with chronic ischemic LV systolic dysfunction who had dobutamine stress echocardiography were studied. Clinical, hemodynamic, and angiographic parameters at rest and low-dose were compared between 38 patients (mean ejection fraction (EF) of 30 +/- 8%) with low-dose SWMA and 32 patients (EF 30 +/- 11%) without low-dose SWMA.
  
  
  RESULTS
  Multivariate analysis showed that the number of coronary territories with severe disease (stenosis > or =70%)(P = 0.001, RR = 6.3) was an independent predictor of low-dose SWMA. An increasing number of collateral vessels protected patients from low-dose SWMA (P = 0.011, RR = 0.25). A higher resting heart rate was a negative predictor of low-dose SWMA (P = 0.015, RR = 0.92) but no other hemodynamic variables were predictors. In the patients with low-dose SMA, regions with low-dose SWMA were more likely to be supplied by vessels with severe disease than regions without low-dose SWMA (92% vs 58%, P < 0.001).
  
  
  CONCLUSIONS
  In patients with ischemic LV systolic dysfunction, the extent of severe disease and a lower numbers of collaterals predict the occurrence of low-dose SWMA. Low-dose SWMA is a highly specific marker for severe disease.
authors.affiliation: Krannert Institute of Cardiology, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA. ssawada@iupui.edu
authors.forename: Stephen G
authors.initials: SG
authors.lastname: Sawada
authors.forename: Anas
authors.initials: A
authors.lastname: Safadi
authors.forename: Rajdeep S
authors.initials: RS
authors.lastname: Gaitonde
authors.forename: Nisha
authors.initials: N
authors.lastname: Tung
authors.forename: Jothiharan
authors.initials: J
authors.lastname: Mahenthiran
authors.forename: William
authors.initials: W
authors.lastname: Gill
authors.forename: Waqas
authors.initials: W
authors.lastname: Ghumman
authors.forename: Irmina
authors.initials: I
authors.lastname: Gradus-Pizlo
authors.forename: Masoor
authors.initials: M
authors.lastname: Kamalesh
authors.forename: Naomi
authors.initials: N
authors.lastname: Fineberg
authors.forename: Harvey
authors.initials: H
authors.lastname: Feigenbaum
mesh_terms: D002316:Cardiotonic Agents / Q000009:adverse effects; D004280:Dobutamine / Q000009:adverse effects*; D004452:Echocardiography / Q000379:methods; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000139:chemically induced* / Q000000981:diagnostic imaging*; D018487:Ventricular Dysfunction, Left / Q000139:chemically induced* / Q000000981:diagnostic imaging*
chemical_list: D002316:Cardiotonic Agents; D004280:Dobutamine